Shares in Vectura are down 11% this morning after publication of interim results. Whilst the share price reaction could be pinned on news of a sharply wider pre-tax loss it may in fact be due to a downgraded Risk & Uncertainties statement, buried half way through the report before the financial statements. Back in May,…
Macro observations As foreign exchange traders return to their desks, news of another North Korean nuclear test have abruptly impacted FX markets. Unless further provocations take place this week, however, the politics and central bank heavy calendar is expected to once again become the primary driver of market sentiment. The headline event of the week…
1 Sept London South East (Link) “Investors have reacted logically to the prospect of even more and accelerated generic competition eroding up to 80% of Indivior’s already waning US market share for the drug ‘within months’,” said Accendo Markets analyst Mike Van Dulken 31 Aug Fox Business (Link) This is some welcome good news from Asia following…
September has only just begun, however already, alongside the acceleration of the expected customary September volume increase, there is a plentiful helping of stocks from one of retail investors’ favourite sector, the Housebuilders. As has almost become customary, the sector wheels some of its largest names out to report numbers almost as soon as the…
It makes sense for investors’ first reaction to a catastrophe such as Hurricane Harvey to be the identification of companies and share prices which may be negatively impacted. The reasons are three-fold. Firstly, am I in these names, do I need to protect profits and/or can I avoid worsening of losses? Secondly, let me keep…
It’s been quite the fall from grace for Indivior shares this morning – down up to 40% to levels traded last July – after a US court ruled that competitor drugs for its Suboxone Film for heroin addiction treatment don’t infringe on its patents. Generic competition has already trimmed Indivior’s US market share for the…